Gain Therapeutics (NASDAQ: GANX)
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Gain Therapeutics (NASDAQ: GANX) through any online brokerage.
There are no as such competitors for Gain Therapeutics.
The latest price target for Gain Therapeutics (NASDAQ: GANX) was reported by B. Riley Securities on Tuesday, March 29, 2022. The analyst firm set a price target for 16.00 expecting GANX to rise to within 12 months (a possible 287.41% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Gain Therapeutics (NASDAQ: GANX) is $4.13 last updated Today at June 28, 2022, 2:24 PM UTC.
There are no upcoming dividends for Gain Therapeutics.
Gain Therapeutics’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Gain Therapeutics.
Gain Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.